Duopharma Biotech Berhad Management

Management Kriterienprüfungen 4/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Leonard bin Abdul Shatar

Geschäftsführender

RM2.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	47.8%
Amtszeit als Geschäftsführer	16.4yrs
Eigentum des Geschäftsführers	n/a
Durchschnittliche Amtszeit des Managements	3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	6.3yrs

Jüngste Management Updates

Recent updates

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Aug 27

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Apr 04

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Feb 17

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Oct 21

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Aug 18

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Aug 07

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Mar 28

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Mar 27

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Nov 26

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Nov 25

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Aug 20

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

May 22

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Apr 13

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Jan 12

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Leonard bin Abdul Shatar im Vergleich zu den Einnahmen von Duopharma Biotech Berhad verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Mar 31 2024	n/a	n/a	RM45m
Dec 31 2023	RM3k	RM1k	RM53m
Sep 30 2023	n/a	n/a	RM61m
Jun 30 2023	n/a	n/a	RM69m
Mar 31 2023	n/a	n/a	RM72m
Dec 31 2022	RM2m	RM1m	RM70m
Sep 30 2022	n/a	n/a	RM69m
Jun 30 2022	n/a	n/a	RM69m
Mar 31 2022	n/a	n/a	RM68m
Dec 31 2021	RM2m	RM1m	RM66m
Sep 30 2021	n/a	n/a	RM66m
Jun 30 2021	n/a	n/a	RM63m
Mar 31 2021	n/a	n/a	RM63m
Dec 31 2020	RM2m	RM924k	RM59m
Sep 30 2020	n/a	n/a	RM54m
Jun 30 2020	n/a	n/a	RM55m
Mar 31 2020	n/a	n/a	RM54m
Dec 31 2019	RM2m	RM882k	RM55m
Sep 30 2019	n/a	n/a	RM58m
Jun 30 2019	n/a	n/a	RM55m
Mar 31 2019	n/a	n/a	RM51m
Dec 31 2018	RM1m	RM876k	RM48m

Vergütung im Vergleich zum Markt: LeonardDie Gesamtvergütung ($USD537.35) liegt unter dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt MY ($USD177.35K).

Entschädigung vs. Einkommen: LeonardDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Leonard bin Abdul Shatar (59 yo)

16.4yrs

Amtszeit

RM2,533

Vergütung

Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ariff bin Abdul Shatar	Group MD & Executive Director	16.4yrs	RM2.53k	keine Daten
Wu Chek	Chief Financial Officer	11.9yrs	keine Daten	0.000010% MYR 119.3
Ibrahim Salleh	Chief Legal Officer & Group Company Secretary	6.5yrs	keine Daten	keine Daten
Sabrina Haron	Chief Compliance Officer	less than a year	keine Daten	keine Daten
Krisnakumara Reddi	Chief Manufacturing & Sustainability Officer	1.7yrs	keine Daten	0.00030% MYR 3.6k
Wan Ahmad Bin Wan Mohd. Salleh	Group Head of Risk Management & Integrity	1.4yrs	keine Daten	keine Daten
Anas Bin Alam Faizli	Chief Executive Officer of Corporate	1.7yrs	keine Daten	keine Daten
Shamsul Bin A. Iahad	Chief Executive Officer of Duopharma Consumer Healthcare Sdn. Bhd.	4.4yrs	keine Daten	keine Daten

3.0yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrenes Management: DPHARMADas Führungsteam des Unternehmens gilt als erfahren (3 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ariff bin Abdul Shatar	Group MD & Executive Director	6.5yrs	RM2.53k	keine Daten
Nik Binti Nik Mohamed Shihabuddin	Independent Non-Executive Director	no data	keine Daten	keine Daten
Razalee Bin Amin	Independent Non-Executive Director	8yrs	RM130.80k	keine Daten
Mohd Bin Mohd Yunus	Non Independent Non Executive Director	6.3yrs	RM146.40k	0.0026% MYR 31.4k
Nik Bin Nik Hassan	Independent Non-Executive Director	6.5yrs	RM143.80k	keine Daten
Zaki Bin Mohamad Zaher	Independent Non-Executive Director	4.8yrs	RM135.40k	keine Daten
Zaiton Binti Jamaluddin	Independent Non Executive Director	7.8yrs	RM143.80k	keine Daten
Eisah Binti Rahman	Senior Independent Non-Executive Director	7.6yrs	RM141.40k	keine Daten
Kartini Binti Abdul Manaf	Non-Independent & Non-Executive Chairman	less than a year	RM76.70k	keine Daten
Muhammad Bin Ismail	Non Independent & Non Executive Alternate Director	less than a year	keine Daten	keine Daten
Mohd Bin Mohd Arshad	Non-Independent & Non-Executive Director	less than a year	keine Daten	keine Daten

6.3yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: DPHARMADie Vorstandsmitglieder gelten als erfahren (6.3 Jahre durchschnittliche Amtszeit).

Duopharma Biotech Berhad Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Recent updates

Duopharma Biotech Berhad Announces Retirement of Tan Sri, Datin Paduka Siti Sa'diah Binti Sh Bakir as Non-Independent and Non-Executive Chairman

New minor risk - Profit margin trend

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Duopharma Biotech Berhad, Annual General Meeting, Jun 06, 2024

Duopharma Biotech Berhad Announces the Resignation of Puan Amizar Binti Mizuar as Non Independent and Non Executive Director

Consensus EPS estimates fall by 11%

Upcoming dividend of RM0.018 per share

Full year 2023 earnings released: EPS: RM0.055 (vs RM0.074 in FY 2022)

Now 20% undervalued

Third quarter 2023 earnings released: EPS: RM0.009 (vs RM0.017 in 3Q 2022)

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005

Price target decreased by 8.3% to RM1.63

Second quarter 2023 earnings released: EPS: RM0.013 (vs RM0.017 in 2Q 2022)

Duopharma Biotech Berhad Declares Interim Dividend for the 30 June 2023, Payable on 22 September 2023

Duopharma Biotech Berhad Appoints ENCIK MUHAMMAD SHUKRI BIN ISMAIL as Non Independent and Non Executive Alternate Director

Duopharma Biotech Berhad Announces Re-Designation of Dato' Eisah Binti A. Rahman, Member of Nomination and Remuneration Committee as Independent and Non-Executive Chairman of Nomination and Remuneration Committee, Date of Change 1 June 2023

Duopharma Biotech Berhad Announces Retirement of Dato' Mohamad Kamarudin Bin Hassan as Independent and Non-Executive Member of Risk Committee

Full year 2022 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018

Upcoming dividend of RM0.018 per share at 1.5% yield

Full year 2022 earnings released: EPS: RM0.074 (vs RM0.071 in FY 2021)

Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price

Price target increased to RM1.81

Insufficient new directors

Third quarter 2022 earnings released: EPS: RM0.017 (vs RM0.018 in 3Q 2021)

Insufficient new directors

These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively

Insufficient new directors

Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005

Second quarter 2022 earnings released: EPS: RM0.017 (vs RM0.016 in 2Q 2021)

Duopharma Biotech Berhad Announces an Interim Dividend, Payable on 14 September 2022

Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad, Annual General Meeting, Jun 21, 2022

Now 21% undervalued after recent price drop

Full year 2021 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of RM0.018 per share

Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year

Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Full year 2021 earnings: EPS and revenues miss analyst expectations

Duopharma Biotech Declares Second Interim Dividend in Respect of the Financial Year Ended 31 December 2021

We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings

Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021

Price target decreased to RM1.97

Third quarter 2021 earnings released: EPS RM0.018 (vs RM0.015 in 3Q 2020)

Investor sentiment deteriorated over the past week

Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005

Second quarter 2021 earnings released: EPS RM0.022 (vs RM0.022 in 2Q 2020)

Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Upcoming dividend of RM0.06 per share

Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend

Price target decreased to RM3.10

A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)

Investor sentiment deteriorated over the past week

New 90-day low: RM3.03

Full year 2020 earnings released: EPS RM0.085 (vs RM0.082 in FY 2019)

Revenue behind estimates

Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly

Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?

Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?

Price target raised to RM2.45

Government of Malaysia, Biocon Sdn. Bhd. and Duopharma Biotech Berhad Extends the Contract Period Under the Agreement One Year Effective from 2 December 2020 Until 1 December 2021

Duopharma Biotech Berhad Announces Temporary Closure of Registered Office

First half earnings released

New 90-day high - RM3.29

Analyse der Geschäftsführervergütung